XENETIC BIOSCIENCES INC. news, videos and press releases
For more news please use our advanced search feature.
XENETIC BIOSCIENCES INC. - More news...
XENETIC BIOSCIENCES INC. - More news...
- Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
- Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
- Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
- Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
- Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
- Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
- Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
- Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
- Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
- Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
- Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
- Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
- Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
- Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
- Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
- Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
- Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
- Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
- Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
- Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
- Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
- Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
- Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
- Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
- Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
- Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
